Xu D, Yu F, Guo T, Zhou Y, et al. Clinical value of PET/CT in identifying patients with oligometastatic /oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons. Br J Radiol 2022 May 25:20220035. doi: 10.1259/bjr.20220035.
PMID: 35611637